Drug intelligence / Profile preview

Lulong Zaisheng Decoction II

Development stage: Unknown
Lead developer: Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Administration: Oral

Overview

Lulong Zaisheng Decoction II is a Traditional Chinese Medicine (TCM) herbal formula developed by the Jiangsu Province Hospital on Integration of Chinese and Western Medicine. It is specifically designed to address chemotherapy-induced leukopenia (CIL) in patients with colorectal cancer. The decoction is intended to support hematopoietic function and mitigate the bone marrow suppression commonly associated with cytotoxic chemotherapy regimens. It is currently being evaluated in clinical trials to determine its efficacy in maintaining white blood cell counts and improving the quality of life for cancer patients undergoing treatment.

Other names: Lulong Zaisheng Decoction IILulong Zaisheng Tang II

Beyond the preview

Go deeper on Lulong Zaisheng Decoction II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lulong Zaisheng Decoction II.

Explore the full profile